Journal article

Association of Body Mass Index and Extreme Obesity With Long-Term Outcomes Following Percutaneous Coronary Intervention

Sinjini Biswas, Nick Andrianopoulos, Diem Dinh, Stephen J Duffy, Jeffrey Lefkovits, Angela Brennan, Samer Noaman, Andrew Ajani, David J Clark, Melanie Freeman, Ernesto Oqueli, Chin Hiew, Christopher M Reid, Dion Stub, William Chan

Journal of the American Heart Association | WILEY | Published : 2019


Background Previous studies have reported a protective effect of obesity compared with normal body mass index (BMI) in patients undergoing percutaneous coronary intervention (PCI). However, it is unclear whether this effect extends to the extremely obese. In this large multicenter registry-based study, we sought to examine the relationship between BMI and long-term clinical outcomes following PCI, and in particular to evaluate the association between extreme obesity and long-term survival after PCI. Methods and Results This cohort study included 25 413 patients who underwent PCI between January 1, 2005 and June 30, 2017, who were prospectively enrolled in the Melbourne Interventional Group r..

View full abstract


Awarded by National Heart Foundation (NHF) of Australia

Awarded by NHMRC

Awarded by NHMRC Principal Research Fellowship

Awarded by NHF Future Leader Fellowship

Funding Acknowledgements

Dr Biswas is supported by scholarships from the National Heart Foundation (NHF) of Australia (reference no. 101518), National Health and Medical Research Council of Australia (NHMRC) Cardiovascular Centre of Research Excellence in Cardiovascular Outcomes Improvement (CRE-COI), and the Australian Government Research Training Program. Dr Noaman is supported by a scholarship from the NHMRC CRE-COI. Professor Duffy's work is supported by a NHMRC grant (reference no. 1111170). Professor Reid is supported by a NHMRC Principal Research Fellowship (reference no. 11136372). Associate Professor Stub is supported by a NHF Future Leader Fellowship (reference no. 101908) and a Viertel Foundation Clinical Investigator award. Associate Professor Chan is supported by the Alfred Hospital Research Trust and the Harold Cora Brennan Benevolent Trust. The Melbourne Interventional Group acknowledges funding from Abbott, Astra-Zeneca, Medtronic, MSD, Pfizer, Servier, and The Medicines Company. These companies do not have access to data and do not have the right to review manuscripts or abstracts before publication. Medtronic also assisted in defraying the publication cost of this article with an unrestricted educational grant.